Christopher J. Sweeney
YOU?
Author Swipe
View article: Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer Open
There is an unmet need for a tool that could predict early favorable prostate-specific antigen (PSA) response in metastatic hormone sensitive prostate cancer (mHSPC) patients receiving androgen receptor pathway inhibitor (ARPI). Here, we t…
View article: Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers Open
Advanced prostate cancers respond to hormone therapy but outcomes vary and no predictive tests exist for informed treatment selection. To identify novel biomarker-treatment pairings, we examined associations between biological pathways and…
View article: EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer
EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer Open
Phenotypic plasticity is a recognized mechanism of therapeutic resistance in prostate cancer (PCa), however current knowledge of driver mechanisms and therapeutic interventions are limited. Using genetically engineered mouse models (GEMMs)…
View article: Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose:A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associatio…
View article: Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 1
View article: Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 2
View article: Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 2
View article: Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 3
View article: Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 1
View article: Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 4
View article: ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose: A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associati…
View article: Circulating tumor <scp>DNA</scp> monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
Circulating tumor <span>DNA</span> monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab Open
Immune checkpoint inhibitors are important for treatment across tumor types but are not universally effective in controlling disease. Early understanding of tumor response, or lack thereof, can inform treatment decisions. This study evalua…
View article: Radioprotective effects of parthenolide lotion against skin injury caused by radiation (REPAIR-1): protocol for a phase 0, non-randomised, double-blind, interventional pilot study
Radioprotective effects of parthenolide lotion against skin injury caused by radiation (REPAIR-1): protocol for a phase 0, non-randomised, double-blind, interventional pilot study Open
Introduction Radiation forms the basis of many successful anti-cancer treatment regimens, killing tumour cells by irreversibly damaging their DNA. Unfortunately, radiation indiscriminately kills healthy cells, causing a range of debilitati…
View article: Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival Open
Cancer progression involves loss of differentiation and acquisition of stem cell-like traits, broadly referred to as “stemness”. Here, we test whether the level of stemness, assessed by a transcriptome-derived Stemness score, can quantitat…
View article: Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer Open
In select subgroups, early treatment intensification with combination therapy leads to improved survival, though it can be associated with long-term toxicity.
View article: Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial Open
Ipatasertib addition to abiraterone did not improve OS for men with mCRPC, regardless of PTEN status on IHC. Exploratory biomarker analyses identified additional genomic alterations of potential clinical relevance for AKT blockade in mCRPC…
View article: Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304) Open
What is this summary about? ENZAMET is a large international clinical trial involving people with metastatic hormone sensitive prostate cancer (mHSPC). Prior to the trial, standard treatment included testosterone suppression and sometimes,…
View article: The influence of soil organic matter content on the toxicity of pesticides to the springtail <i>Folsomia candida</i>
The influence of soil organic matter content on the toxicity of pesticides to the springtail <i>Folsomia candida</i> Open
The European environmental risk assessment (ERA) of pesticides to soil invertebrates applies a correction factor (CF) of 2 to endpoints derived from toxicity tests with lipophilic pesticides (log Kow > 2) to correct for differences in o…
View article: Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer Open
The CHAARTED study showed that adding docetaxel (Doc) to androgen deprivation therapy (ADT) in men initiating treatment for metastatic hormone-sensitive prostate cancer (mHSPC) prolongs survival, particularly in high-volume disease. Androg…
View article: Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice Open
Phenotypic plasticity is a hallmark of cancer and is increasingly realized as a mechanism of resistance to androgen receptor-targeted (AR-targeted) therapy. Now that many prostate cancer (PCa) patients are treated upfront with AR-targeted …
View article: Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance Open
BACKGROUNDMetastatic hormone-sensitive prostate cancer (mHSPC) is androgen dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal testosterone suppression. Since 2014, overall survival (OS) has been prolonged…
View article: Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
Purpose:Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit. Analyzing IMbassador250, a phase III trial assessing enzalutamide with or withou…
View article: Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
ctDNA TF response is more closely correlated with survival than PSA50 response in discordant cases
View article: Supplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
ctDNA tumor fraction pre-enzalutamide to prognosticate overall survival and progression-free survival on enzalutamide post-abiraterone
View article: Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
Prognostic value of on-treatment ctDNA TF detection and 90% PSA reduction